Publications by authors named "A Cutino"

Objectives: The COVID-19 pandemic has negatively impacted child and adolescent mental health. The study outcome was the evaluation of the pandemic impact on adolescents' hospitalizations in an acute psychiatric ward.

Methods: With an observational and retrospective design, we collected selected variables among adolescents hospitalized in an acute psychiatric ward from 01/07/2017 to 30/06/2022.

View Article and Find Full Text PDF

Conventional systems used to tag and transfer symbiotic plasmids (pSyms) of rhizobial strains are based in mutagenesis with transposons. In those processes, numerous clones must be analyzed to find one of them with the transposon inserted in the pSym. Following this strategy, the insertion might interrupt a gene that can affect the symbiotic phenotype of the bacteria tagged.

View Article and Find Full Text PDF
Article Synopsis
  • The study evaluated the outcomes of using a 0.19-mg fluocinolone acetonide (FAc) implant and IOP-lowering surgery in patients with diabetic macular edema over 36 months.
  • Out of 202 eyes, only 8 required surgery due to increased intraocular pressure (IOP), which was categorized as either FAc-induced or neovascular glaucoma (NVG)-related.
  • The results showed slight improvements in visual acuity, but IOP and central subfield thickness remained unchanged; FAc-induced cases used fewer but longer-lasting medications compared to NVG cases.
View Article and Find Full Text PDF

To assess the impact of retinal thickness variability (RTV) control on visual and treatment burden outcomes in patients with diabetic macular edema (DME) who received the 0.19 mg fluocinolone acetonide (FAc) intravitreal implant (Iluvien, Alimera Sciences). This post hoc analysis examined the outcomes of a 3-year, phase 4, nonrandomized, open-label observational study.

View Article and Find Full Text PDF

Purpose: To evaluate effects of the 0.19-mg fluocinolone acetonide (FAc) intravitreal implant (ILUVIEN) on intraocular pressure (IOP) in patients with diabetic macular edema (DME).

Design: Secondary analysis of a 36-month, phase IV, nonrandomized, open-label, observational study.

View Article and Find Full Text PDF